Analyses drawn from the propensity-matched sample showed improved primary efficacy end point in the tirofiban group at 30-day ( OR 0.72 , 95 % CI 0.53-0 .97 ) and at 1-year ( OR 0.74 , 95 % CI 0.57-0 .96 ) follow up .